NCT04028063 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04028063
Title	Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	University of Colorado, Denver
Indications	hemangiopericytoma pleomorphic liposarcoma myoepithelioma spindle cell sarcoma malignant peritoneal solitary fibrous tumor malignant pleural solitary fibrous tumor uterus leiomyosarcoma leiomyosarcoma synovial sarcoma dedifferentiated liposarcoma malignant peripheral nerve sheath tumor myxoid liposarcoma angiosarcoma myxofibrosarcoma sarcoma fibrosarcoma malignant epithelioid hemangioendothelioma
Therapies	Botensilimab + Doxorubicin Balstilimab + Doxorubicin + Zalifrelimab
Age Groups:	senior \| adult
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
University of Colorado Hospital	RECRUITING	Aurora	Colorado	80045	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT04028063Clinical Trial Detail